In this study, we also found that SS-1 inhibited splenic T cell proliferation (Figure 4A), Th1 (CD4+ IFN-γ+) and Th17 (CD4+ IL-17+) cells (Figure 4C,D), and reduced the levels of cytokines (IFN-γ and IL-17) in a salivary gland-induced SS-like symptom mouse model (Figure 4B). Here, IL17A is linked to synovial sarcoma.